Many early stage biotechs rely on obvious strengths of their assembled team and omit to complement areas of potential weakness in their knowledge portfolio.​
 

This can undermine efficiency of project execution and necessitate backtracking and re-calibration.
 

In some cases, this affects achievement of preliminary milestones with real impact on potential valuation.
 

In an increasingly competitive field, inefficiencies in strategy can delay proof of concept execution and retard momentum to first mover advantage.
 

These limitations impact both developers of therapy and increase unseen risk for investors.